Vyriad

Vyriad is a clinical-stage biotechnology company formed by the strategic merger between Omnis Pharma and Magnis Therapeutics that develops novel oncolytic virus therapies for the treatment of cancers that have significant unmet need.In May 2018, Vyriad announced signing of a contract to build out state-of-the-art facility in 25,000 square feet of leased space on the IBM Campus in Rochester, Minnesota. The initial buildout was commencing immediately and planned to have the facility fully operational in the fourth quarter of 2018.In May 2022, the company announced USD 29.5M in new funding led by Mr Harry Stine of Stine Seed Farms, Inc. This round adds to a prior closing for Vyriad's Series B round and brings total funds raised by Vyriad since 2015 to over USD 100M